Immuno-Biological LaboratoriesImmuno-Biological Laboratories Co., Ltd.4570東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP

Immuno-Biological Laboratories FY ending Mar 2020 results

About 81% of Immuno-Biological Laboratories's sales come from Diagnosis and reagent, with Inspection and Gene recombination silkworm making up much of the rest.

It lost about ¥103 for every ¥100 of sales at the operating level.

Where the money goes

Where ¥100 of sales goes

For every ¥100 Immuno-Biological Laboratories sells, how much goes where, and how much is kept.

FY ending Mar 2020

Cost of sales: ¥62
SG&A: ¥141
Operating loss: ¥103
Net loss: ¥116

Margin funnel (derived from reported values)Gross margin 37.7% → Operating margin -103.2% → Net margin -115.9%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

Diagnosis and reagent¥468.6M
81%
Op. margin -26.6%
Inspection¥70M
12%
Op. margin -37.5%
Gene recombination silkworm¥25.2M
4%
Op. margin -1552.4%
Cosmetics¥12.9M
2%
Op. margin -417.5%Industry: Cosmetics

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第42期(2023/04/01－2024/03/31)
ID S100TTJJ2024-06-26Open
EDINET (FSA Japan)
有価証券報告書－第40期(令和3年4月1日－令和4年3月31日)
ID S100OIQD2022-06-30Open
EDINET (FSA Japan)
訂正有価証券報告書－第39期(令和2年4月1日－令和3年3月31日)
ID S100N41B2021-12-22Open

Extracted from XBRL: 39

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image